Is QDEL or RXST more profitable?

RxSight has a net margin of -36.80% compared to QuidelOrtho's net margin of -39.20%. QuidelOrtho's return on equity of 4.88% beat RxSight's return on equity. Company Net Margins Return on Equity Return on Assets QuidelOrtho -39.20% 4.88% 1.63% RxSight -36.80% -17.35% -14.70%

Does the media refer more to QDEL or RXST?

In the previous week, RxSight had 1 more articles in the media than QuidelOrtho. MarketBeat recorded 8 mentions for RxSight and 7 mentions for QuidelOrtho. QuidelOrtho's average media sentiment score of 0.52 beat RxSight's score of 0.36 indicating that QuidelOrtho is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment QuidelOrtho 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RxSight 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, CERS or RXST?

Cerus has higher revenue and earnings than RxSight. Cerus is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cerus $206.13M 2.23 -$15.63M -$0.03 N/A RxSight $134.48M 1.50 -$38.94M -$1.13 N/A

Is CERS or RXST more profitable?

Cerus has a net margin of -3.06% compared to RxSight's net margin of -36.80%. Cerus' return on equity of -10.19% beat RxSight's return on equity. Company Net Margins Return on Equity Return on Assets Cerus -3.06% -10.19% -3.14% RxSight -36.80% -17.35% -14.70%

Does the media refer more to CERS or RXST?

In the previous week, RxSight had 6 more articles in the media than Cerus. MarketBeat recorded 8 mentions for RxSight and 2 mentions for Cerus. Cerus' average media sentiment score of 0.60 beat RxSight's score of 0.36 indicating that Cerus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RxSight 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, EMBC or RXST?

Embecta has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Embecta $1.08B 0.30 $95.40M $1.48 3.89 RxSight $134.48M 1.50 -$38.94M -$1.13 N/A

Is EMBC or RXST more profitable?

Embecta has a net margin of 8.59% compared to RxSight's net margin of -36.80%. RxSight's return on equity of -17.35% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets Embecta 8.59% -19.25% 10.82% RxSight -36.80% -17.35% -14.70%

Is SMTI or RXST more profitable?

Sanara MedTech has a net margin of -29.15% compared to RxSight's net margin of -36.80%. Sanara MedTech's return on equity of 29.72% beat RxSight's return on equity. Company Net Margins Return on Equity Return on Assets Sanara MedTech -29.15% 29.72% 2.84% RxSight -36.80% -17.35% -14.70%

Does the media refer more to SMTI or RXST?

In the previous week, RxSight had 6 more articles in the media than Sanara MedTech. MarketBeat recorded 8 mentions for RxSight and 2 mentions for Sanara MedTech. RxSight's average media sentiment score of 0.36 beat Sanara MedTech's score of 0.17 indicating that RxSight is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanara MedTech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral RxSight 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor OSUR or RXST?

In the previous week, RxSight had 5 more articles in the media than OraSure Technologies. MarketBeat recorded 8 mentions for RxSight and 3 mentions for OraSure Technologies. OraSure Technologies' average media sentiment score of 0.48 beat RxSight's score of 0.36 indicating that OraSure Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OraSure Technologies 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral RxSight 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

RxSight (RXST) Competitors

$4.80 -0.05 (-0.93%)

Closing price 03:59 PM Eastern

Extended Trading

$4.82 +0.01 (+0.21%)

As of 04:01 PM Eastern

Compare

RXST vs. QDEL, CERS, EMBC, SMTI, and OSUR

Should you buy RxSight stock or one of its competitors? RxSight's main competitors and comparable companies include QuidelOrtho (QDEL), Cerus (CERS), Embecta (EMBC), Sanara MedTech (SMTI), and OraSure Technologies (OSUR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does RxSight compare to QuidelOrtho?

QuidelOrtho (NASDAQ:QDEL) and RxSight (NASDAQ:RXST) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

99.0% of QuidelOrtho shares are held by institutional investors. Comparatively, 78.8% of RxSight shares are held by institutional investors. 1.1% of QuidelOrtho shares are held by insiders. Comparatively, 10.1% of RxSight shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

QuidelOrtho has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, RxSight has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market.

RxSight has a net margin of -36.80% compared to QuidelOrtho's net margin of -39.20%. QuidelOrtho's return on equity of 4.88% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
QuidelOrtho	-39.20%	4.88%	1.63%
RxSight	-36.80%	-17.35%	-14.70%

In the previous week, RxSight had 1 more articles in the media than QuidelOrtho. MarketBeat recorded 8 mentions for RxSight and 7 mentions for QuidelOrtho. QuidelOrtho's average media sentiment score of 0.52 beat RxSight's score of 0.36 indicating that QuidelOrtho is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
QuidelOrtho	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RxSight	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

QuidelOrtho currently has a consensus price target of $13.63, suggesting a potential upside of 9.79%. RxSight has a consensus price target of $8.17, suggesting a potential upside of 68.50%. Given RxSight's stronger consensus rating and higher probable upside, analysts plainly believe RxSight is more favorable than QuidelOrtho.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

RxSight has lower revenue, but higher earnings than QuidelOrtho. RxSight is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QuidelOrtho	$2.73B	0.31	-$1.13B	-$15.41	N/A
RxSight	$134.48M	1.50	-$38.94M	-$1.13	N/A

Summary

RxSight beats QuidelOrtho on 10 of the 16 factors compared between the two stocks.

How does RxSight compare to Cerus?

Cerus (NASDAQ:CERS) and RxSight (NASDAQ:RXST) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Cerus has a beta of 1.83, suggesting that its share price is 83% more volatile than the broader market. Comparatively, RxSight has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

Cerus has a net margin of -3.06% compared to RxSight's net margin of -36.80%. Cerus' return on equity of -10.19% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-3.06%	-10.19%	-3.14%
RxSight	-36.80%	-17.35%	-14.70%

Cerus has higher revenue and earnings than RxSight. Cerus is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$206.13M	2.23	-$15.63M	-$0.03	N/A
RxSight	$134.48M	1.50	-$38.94M	-$1.13	N/A

In the previous week, RxSight had 6 more articles in the media than Cerus. MarketBeat recorded 8 mentions for RxSight and 2 mentions for Cerus. Cerus' average media sentiment score of 0.60 beat RxSight's score of 0.36 indicating that Cerus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cerus	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RxSight	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cerus currently has a consensus target price of $5.25, indicating a potential upside of 130.26%. RxSight has a consensus target price of $8.17, indicating a potential upside of 68.50%. Given Cerus' stronger consensus rating and higher probable upside, equities research analysts plainly believe Cerus is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

78.4% of Cerus shares are held by institutional investors. Comparatively, 78.8% of RxSight shares are held by institutional investors. 5.3% of Cerus shares are held by insiders. Comparatively, 10.1% of RxSight shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Cerus beats RxSight on 12 of the 16 factors compared between the two stocks.

How does RxSight compare to Embecta?

Embecta (NASDAQ:EMBC) and RxSight (NASDAQ:RXST) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

Embecta has a net margin of 8.59% compared to RxSight's net margin of -36.80%. RxSight's return on equity of -17.35% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	8.59%	-19.25%	10.82%
RxSight	-36.80%	-17.35%	-14.70%

In the previous week, RxSight had 8 more articles in the media than Embecta. MarketBeat recorded 8 mentions for RxSight and 0 mentions for Embecta. RxSight's average media sentiment score of 0.36 beat Embecta's score of 0.00 indicating that RxSight is being referred to more favorably in the news media.

Company	Overall Sentiment
Embecta	Neutral
RxSight	Neutral

Embecta currently has a consensus price target of $11.00, indicating a potential upside of 91.30%. RxSight has a consensus price target of $8.17, indicating a potential upside of 68.50%. Given Embecta's higher probable upside, equities analysts plainly believe Embecta is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

Embecta has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, RxSight has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

Embecta has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08B	0.30	$95.40M	$1.48	3.89
RxSight	$134.48M	1.50	-$38.94M	-$1.13	N/A

93.8% of Embecta shares are held by institutional investors. Comparatively, 78.8% of RxSight shares are held by institutional investors. 1.3% of Embecta shares are held by company insiders. Comparatively, 10.1% of RxSight shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Embecta and RxSight tied by winning 8 of the 16 factors compared between the two stocks.

How does RxSight compare to Sanara MedTech?

Sanara MedTech (NASDAQ:SMTI) and RxSight (NASDAQ:RXST) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

8.1% of Sanara MedTech shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 42.0% of Sanara MedTech shares are owned by company insiders. Comparatively, 10.1% of RxSight shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Sanara MedTech has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market. Comparatively, RxSight has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

Sanara MedTech has a net margin of -29.15% compared to RxSight's net margin of -36.80%. Sanara MedTech's return on equity of 29.72% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-29.15%	29.72%	2.84%
RxSight	-36.80%	-17.35%	-14.70%

Sanara MedTech has higher earnings, but lower revenue than RxSight. Sanara MedTech is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$103.12M	3.12	-$37.56M	-$3.59	N/A
RxSight	$134.48M	1.50	-$38.94M	-$1.13	N/A

Sanara MedTech currently has a consensus price target of $35.00, suggesting a potential downside of 0.14%. RxSight has a consensus price target of $8.17, suggesting a potential upside of 68.50%. Given RxSight's stronger consensus rating and higher probable upside, analysts clearly believe RxSight is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

In the previous week, RxSight had 6 more articles in the media than Sanara MedTech. MarketBeat recorded 8 mentions for RxSight and 2 mentions for Sanara MedTech. RxSight's average media sentiment score of 0.36 beat Sanara MedTech's score of 0.17 indicating that RxSight is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanara MedTech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
RxSight	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

RxSight beats Sanara MedTech on 9 of the 16 factors compared between the two stocks.

How does RxSight compare to OraSure Technologies?

OraSure Technologies (NASDAQ:OSUR) and RxSight (NASDAQ:RXST) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

RxSight has a net margin of -36.80% compared to OraSure Technologies' net margin of -43.70%. RxSight's return on equity of -17.35% beat OraSure Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OraSure Technologies	-43.70%	-19.09%	-16.26%
RxSight	-36.80%	-17.35%	-14.70%

OraSure Technologies currently has a consensus target price of $3.00, suggesting a potential downside of 21.05%. RxSight has a consensus target price of $8.17, suggesting a potential upside of 68.50%. Given RxSight's stronger consensus rating and higher probable upside, analysts plainly believe RxSight is more favorable than OraSure Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OraSure Technologies	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

93.5% of OraSure Technologies shares are held by institutional investors. Comparatively, 78.8% of RxSight shares are held by institutional investors. 4.7% of OraSure Technologies shares are held by company insiders. Comparatively, 10.1% of RxSight shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

OraSure Technologies has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market. Comparatively, RxSight has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

In the previous week, RxSight had 5 more articles in the media than OraSure Technologies. MarketBeat recorded 8 mentions for RxSight and 3 mentions for OraSure Technologies. OraSure Technologies' average media sentiment score of 0.48 beat RxSight's score of 0.36 indicating that OraSure Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OraSure Technologies	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
RxSight	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

RxSight has higher revenue and earnings than OraSure Technologies. OraSure Technologies is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OraSure Technologies	$115.02M	2.28	-$68.73M	-$0.69	N/A
RxSight	$134.48M	1.50	-$38.94M	-$1.13	N/A

Summary

RxSight beats OraSure Technologies on 12 of the 16 factors compared between the two stocks.

Get RxSight News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RXST vs. The Competition

Export

Metric	RxSight	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$199.84M	$5.44B	$7.19B	$13.28B
Dividend Yield	N/A	1.78%	2.53%	16.36%
P/E Ratio	-4.25	25.51	274.47	26.16
Price / Sales	1.49	71.20	585.00	81.25
Price / Cash	N/A	32.10	76.82	53.72
Price / Book	0.72	5.93	11.21	6.34
Net Income	-$38.94M	$146.18M	$3.50B	$381.90M
7 Day Performance	2.67%	-0.23%	-0.83%	-1.36%
1 Month Performance	-24.09%	-3.20%	-5.42%	-4.29%
1 Year Performance	-40.75%	2.86%	4.36%	-0.33%

RxSight Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
RXST RxSight	2.5311 of 5 stars	$4.81 -0.9%	$8.17 +70.1%	-40.9%	$199.84M	$134.48M	N/A	461
QDEL QuidelOrtho	1.3623 of 5 stars	$10.55 -2.6%	$13.63 +29.1%	-55.5%	$723.76M	$2.73B	N/A	6,500
CERS Cerus	1.6488 of 5 stars	$2.46 +0.2%	$5.25 +113.8%	+35.7%	$494.73M	$206.13M	N/A	345
EMBC Embecta	4.0862 of 5 stars	$5.72 -3.6%	$11.00 +92.5%	-58.4%	$324.95M	$1.08B	3.88	1,850
SMTI Sanara MedTech	0.6747 of 5 stars	$35.06 -0.1%	$35.00 -0.2%	+8.4%	$322.25M	$103.12M	N/A	108

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RXST) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

RxSight (RXST) Competitors